Biopolym. Cell. 1989; 5(3):95-101.
Structure and Function of Biopolymers
Monoclonal antibodies for one-step isolation of highly purified urokinase
1Kraiasyuk G. A., 1Jakubov L. Z., 1Sinitsyn V. V., 1Domogatsky S. P., 1Rohklin O. V., 3Koltsova S. V., 2Bynyaeva N. A., 2Fedorova Z. D., 3Samsonov G. V.
  1. Research Institute of Experimental Cardiology, National Cardiological Research Centre, Academy of Medical Sciences of the USSR
    Moscow, USSR
  2. Institute of Haematology and Blood Transfusion, Ministry of Public Health of the RSFSR
    Leningrad, USSR
  3. Institute of High-Molecular Weight Compounds, Academy of Sciences of the USSR
    Leningrad, USSR

Abstract

Five independent hybridom clones producing monoclonal antibodies with high affinity and specificity for human urokinase are isolated using specially adopted screening technique. Both inhibiting urokinase activity and noninhibiting antibodies are obtained. They do not crossreact with other serin proteases and some of them have dissociation constants lower than 10 pmol/1. Immunosorbents with these monoclonal antibodies are effective for isolation of urokinase from urine: 2 mg of antibodies attached to 1 ml of sepharose binds 0.5 mg of urokinase.

References

[1] Colleti D. On the regulation and control of fibrinolysis. Thromb Haemost. 1981; 43(2):77-89.
[2] Bertele V, Salzman EW. Antithrombotic therapy in coronary artery disease. Arteriosclerosis. 1985;5(2):119-34.
[3] Shibatani T, Kakimoto T, Chibata I. Purification of high molecular weight urokinase from human urine and comparative study of two active forms of urokinase. Thromb Haemost. 1983;49(2):91-5.
[4] Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys. 1983;220(1):31-8.
[5] Huber K, Kirchheimer J, Binder BR. Rapid isolation of high molecular weight urokinase from native human urine. Thromb Haemost. 1982;47(3):197-202.
[6] Kol'tsova SV, Shataeva LK, Sukhareva TF, Byniaeva NA, Fedorova ZD. Isolation and purification of urokinase. Vopr Med Khim. 1981;27(5):623-6.
[7] Petrosian MN, ChervonskiÄ­ AV, Ibragimov AR, Vengerova TI, Brondz BD. Expression of light-chain immunoglobulin allelic genes in hybrid lymphoid cells. Dokl Akad Nauk SSSR. 1981;256(2):509-12.
[8] Van Mourik P, Rivero RA, Van der Kwast TH, Lansdorp PM, Zeijlemaker WP. Density separation of spleen cells increases fusion frequency and yield of Ig-producing hybridomas. J Immunol Methods. 1984;68(1-2):45-53.
[9] Astrup T, Mullertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys. 1952;40(2):346-51.
[10] Friberger P, Knös M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis. 1978;7(2-3):138-45.
[11] Sumi H, Robbins KC. A functionally active heavy chain derived from human high molecular weight urokinase. J Biol Chem. 1983;258(13):8014-9.
[12] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-5.
[13] Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med. 1978;148(1):223-34.
[14] Nielsen LS, Hansen JG, Andreasen PA, Skriver L, Danø K, Zeuthen J. Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification. EMBO J. 1983;2(1):115-9.
[15] Skriver L, Larsson LI, Kielberg V, Nielsen LS, Andresen PB, Kristensen P, Dano K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol. 1984;99(2):753-7.